Durable discontinuation of systemic therapy for chronic graft--host disease: myth or reality?
作者信息
Pavletic Steven Z, Schultz Kirk R
机构信息
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Pediatric Hematology/Oncology/BMT, BC Children's Hospital, Vancouver, British Columbia, Canada.
出版信息
Haematologica. 2023 Feb 1;108(2):303-305. doi: 10.3324/haematol.2022.281114.
Abstract
摘要
相似文献
1
Durable discontinuation of systemic therapy for chronic graft--host disease: myth or reality?慢性移植物抗宿主病全身治疗的持久停药：神话还是现实？
Haematologica. 2023 Feb 1;108(2):303-305. doi: 10.3324/haematol.2022.281114.
2
[Lung transplantation for chronic graft-versus-host disease after hematopoietic stem cell transplantation].造血干细胞移植后慢性移植物抗宿主病的肺移植
Rev Mal Respir. 2023 Mar;40 Suppl 1:e69-e72. doi: 10.1016/j.rmr.2022.12.009. Epub 2023 Jan 20.
3
Durable discontinuation of systemic therapy in patients affected by chronic graft--host disease.慢性移植物抗宿主病患者的系统性治疗的持久停药。
Haematologica. 2023 Feb 1;108(2):483-489. doi: 10.3324/haematol.2021.279814.
4
Case series: CYP Inhibition and low dose ibrutinib for steroid-refractory chronic graft-versus-host disease.病例系列：CYP抑制与低剂量伊布替尼治疗类固醇难治性慢性移植物抗宿主病
Br J Haematol. 2023 May;201(3):573-576. doi: 10.1111/bjh.18712. Epub 2023 Mar 1.
5
Patient-reported treatment response in chronic graft--host disease.慢性移植物抗宿主病中患者报告的治疗反应
Haematologica. 2024 Jan 1;109(1):11-12. doi: 10.3324/haematol.2023.283524.
6
Severe relapses of cutaneous T-cell lymphoma after treatment of chronic graft-versus-host disease with ruxolitinib.用鲁索替尼治疗慢性移植物抗宿主病后皮肤T细胞淋巴瘤的严重复发
J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e32-e34. doi: 10.1111/jdv.19408. Epub 2023 Aug 23.
7
The macrophage activation marker sCD163 in acute and chronic graft-versus-host disease after pediatric hematopoietic stem cell transplantation.小儿造血干细胞移植后急慢性移植物抗宿主病中的巨噬细胞活化标志物可溶性CD163
Bone Marrow Transplant. 2023 May;58(5):587-589. doi: 10.1038/s41409-023-01927-3. Epub 2023 Jan 31.
8
The Importance of Treatment Response for Outcome of Patients With Chronic Graft-Versus-Host Disease.治疗反应对慢性移植物抗宿主病患者结局的重要性。
Transplant Cell Ther. 2024 Jun;30(6):556-558. doi: 10.1016/j.jtct.2024.05.005.
9
[Chronic graft-versus-host disease].[慢性移植物抗宿主病]
Tidsskr Nor Laegeforen. 2023 Mar 13;143(4). doi: 10.4045/tidsskr.22.0525. Print 2023 Mar 14.
10
Isolated massive pleural effusion as a manifestation of chronic graft versus host disease successfully treated with corticosteroid.孤立性大量胸腔积液作为慢性移植物抗宿主病的表现，经皮质类固醇治疗后成功缓解。
Ann Hematol. 2024 Apr;103(4):1403-1407. doi: 10.1007/s00277-024-05643-w. Epub 2024 Jan 29.
引用本文的文献
1
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part I. Phases of Chronic GVHD, Supportive Care, and Systemic Therapy Discontinuation.儿科移植与细胞治疗联盟造血细胞移植后儿科慢性移植物抗宿主病生存的RESILIENT会议：第一部分。慢性移植物抗宿主病的阶段、支持治疗和全身治疗的中断
Transplant Cell Ther. 2025 Feb;31(2):69.e1-69.e18. doi: 10.1016/j.jtct.2024.12.011. Epub 2024 Dec 17.
本文引用的文献
1
Durable discontinuation of systemic therapy in patients affected by chronic graft--host disease.慢性移植物抗宿主病患者的系统性治疗的持久停药。
Haematologica. 2023 Feb 1;108(2):483-489. doi: 10.3324/haematol.2021.279814.
2
Three US Food and Drug Administration-approved therapies for chronic GVHD.三种美国食品和药物管理局批准的慢性移植物抗宿主病治疗方法。
Blood. 2022 Mar 17;139(11):1642-1645. doi: 10.1182/blood.2021014448.
3
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.随机 III 期 BMT CTN 试验：在血液恶性肿瘤的清髓性造血细胞移植中，钙调神经磷酸酶抑制剂免费的慢性移植物抗宿主病干预。
J Clin Oncol. 2022 Feb 1;40(4):356-368. doi: 10.1200/JCO.21.02293. Epub 2021 Dec 2.
4
Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.慢性移植物抗宿主病患者的非复发死亡率：慢性移植物抗宿主病联盟的更新分析。
Blood Adv. 2021 Oct 26;5(20):4278-4284. doi: 10.1182/bloodadvances.2021004941.
5
The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports.慢性移植物抗宿主病的未来：2020年美国国立卫生研究院共识发展项目报告简介
Transplant Cell Ther. 2021 Jun;27(6):448-451. doi: 10.1016/j.jtct.2021.02.034. Epub 2021 Mar 2.
6
Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease.免疫抑制治疗慢性移植物抗宿主病患者的疗效。
Biol Blood Marrow Transplant. 2018 Mar;24(3):555-562. doi: 10.1016/j.bbmt.2017.10.042. Epub 2017 Nov 10.
7
Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients.严重慢性移植物抗宿主病患者中导致系统性免疫抑制永久停药的预测因素。
Biol Blood Marrow Transplant. 2017 Nov;23(11):1980-1988. doi: 10.1016/j.bbmt.2017.08.005. Epub 2017 Aug 7.
8
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.使用移植后环磷酰胺进行 HLA 匹配的亲属或非亲属骨髓移植后免疫抑制负担较低。
Blood. 2017 Mar 9;129(10):1389-1393. doi: 10.1182/blood-2016-09-737825. Epub 2017 Jan 3.
9
Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.异基因外周血干细胞移植后慢性移植物抗宿主病的预后因素：美国国立卫生研究院量表加上发病类型可预测生存率和免疫抑制治疗持续时间。
Biol Blood Marrow Transplant. 2008 Oct;14(10):1163-1171. doi: 10.1016/j.bbmt.2008.07.015.
10
Duration of immunosuppressive treatment for chronic graft-versus-host disease.慢性移植物抗宿主病免疫抑制治疗的持续时间。
Blood. 2004 Dec 1;104(12):3501-6. doi: 10.1182/blood-2004-01-0200. Epub 2004 Aug 3.
Zotero 插件